Cargando…

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

The pathogenesis of acute myeloid leukemia (AML) involves serial acquisition of mutations controlling several cellular processes, requiring combination therapies affecting key downstream survival nodes in order to treat the disease effectively. The BCL2 selective inhibitor venetoclax has potent anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Lina, Zhang, Qi, Dail, Monique, Shi, Ce, Cavazos, Antonio, Ruvolo, Vivian R., Zhao, Yang, Kim, Eugene, Rahmani, Mohamed, Mak, Duncan H., Jin, Sha S., Chen, Jun, Phillips, Darren C., Koller, Paul Bottecelli, Jacamo, Rodrigo, Burks, Jared K., DiNardo, Courtney, Daver, Naval, Jabbour, Elias, Wang, Jing, Kantarjian, Hagop M., Andreeff, Michael, Grant, Steven, Leverson, Joel D., Sampath, Deepak, Konopleva, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2020
Materias:	Aticle
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049339/ https://www.ncbi.nlm.nih.gov/pubmed/31123034 http://dx.doi.org/10.3324/haematol.2018.205534

Ejemplares similares

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020)

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia
por: Bill, Marius, et al.
Publicado: (2020)

Case Report: Severe COVID-19 and Dengue in an Indonesian Infant
por: Alam, Anggraini, et al.
Publicado: (2021)

Human KIAA1018/FAN1 nuclease is a new mitotic substrate of APC/C(Cdh1)
por: Lai, Fenju, et al.
Publicado: (2012)

Health-related Quality of Life of Nurses Working in Tertiary Care Hospital of Karachi
por: Ali, Amjad, et al.
Publicado: (2020)

Epilepsy monitoring units in Saudi Arabia:: Where do we stand compared to developed countries?
por: Aljafen, Bandar N., et al.
Publicado: (2018)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
por: Chyla, Brenda, et al.
Publicado: (2018)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
por: Konopleva, Marina, et al.
Publicado: (2022)

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill F LT 3-ITD acute myeloid leukemia
por: Post, Sean M., et al.
Publicado: (2021)

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
por: Borthakur, Gautam, et al.
Publicado: (2015)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
por: Nishida, Yuki, et al.
Publicado: (2023)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Senapati, Jayastu, et al.
Publicado: (2023)

P736: ANALYSIS OF RESPONSE RATES AND OUTCOMES IN ERYTHROID-PREDOMINANT MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH VENETOCLAX-BASED REGIMENS
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
por: Maiti, Abhishek, et al.
Publicado: (2021)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
por: Gibson, Amber, et al.
Publicado: (2021)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
por: Senapati, Jayastu, et al.
Publicado: (2023)

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34(+) proliferating and quiescent chronic myeloid leukemia blast crisis cells
por: Carter, Bing Z., et al.
Publicado: (2015)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

P485: AZACITIDINE, VENETOCLAX AND GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA: A SUBGROUP ANALYSIS FROM A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors
por: Sasaki, Koji, et al.
Publicado: (2015)

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
por: Mali, Raghuveer Singh, et al.
Publicado: (2020)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

Impact of frontline treatment approach on outcomes of myeloid blast phase CML
por: Saxena, Kapil, et al.
Publicado: (2021)

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network
por: Carter, Bing Z., et al.
Publicado: (2016)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
por: Isidori, Alessandro, et al.
Publicado: (2021)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
por: Zhang, Weiguo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_58tkab1s5t7kjsf1kgj6os6782